AstraZeneca’s Brilinta offers benefits despite higher bleeding risk: Trial

March 15, 2015 5:20 PM

34 0

AstraZeneca’s heart drug Brilinta has been found effective in reducing the risk of second heart attack and death among heart patients. The blood thinner given in combination with aspirin has produced positive results during clinical trials. The medical experts associated with the research have indicated that the drug increases the bleeding risk over long term use.

The study was funded by AstraZeneca, and was scheduled for presentation Saturday in San Diego at the annual meeting of the American College of Cardiology (ACC).

Read more

To category page